Hubert van Hoogstraten Selected Research

sarilumab

4/2022	Pharmacokinetics, Pharmacodynamics and Safety of Single-Dose Subcutaneous Sarilumab With or Without Methotrexate in Japanese Patients with Rheumatoid Arthritis: Two Single-Dose Studies.
1/2022	Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis.
12/2021	Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data.
12/2021	Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data.
1/2021	Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate.
11/2020	Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial.
10/2020	Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
3/2020	Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA).
1/2020	Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
10/2019	Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hubert van Hoogstraten Research Topics

Disease

24	Rheumatoid Arthritis 04/2022 - 06/2015
6	Infections 10/2020 - 06/2015
5	Pain (Aches) 01/2022 - 01/2016
4	Neutropenia 04/2022 - 05/2017
4	Fatigue 01/2022 - 01/2016
4	Chronic Disease (Chronic Diseases) 01/2022 - 01/2016
3	Necrosis 10/2020 - 01/2017
2	Erythema 01/2019 - 01/2018
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2019 - 01/2018
1	Joint Diseases (Joint Disease) 12/2021
1	Coinfection 10/2021
1	COVID-19 10/2021
1	Thrombosis (Thrombus) 01/2020
1	Acute-Phase Reaction 01/2020
1	Inflammation (Inflammations) 01/2020
1	Nasopharyngitis 01/2019
1	Rheumatic Diseases (Rheumatism) 01/2019
1	Nausea 01/2019
1	Headache (Headaches) 05/2017
1	Injection Site Reaction 05/2017

Drug/Important Bio-Agent (IBA)

24	sarilumabIBA 04/2022 - 06/2015
12	Methotrexate (Mexate)FDA LinkGeneric 04/2022 - 06/2015
6	Antirheumatic Agents (DMARD)IBA 10/2020 - 01/2017
4	tocilizumab (atlizumab)FDA Link 04/2022 - 01/2019
4	ametantrone (HAQ)IBA 01/2019 - 01/2016
3	Interleukin-6 (Interleukin 6)IBA 10/2021 - 01/2020
3	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2021 - 01/2018
3	Adalimumab (Humira)FDA Link 01/2020 - 05/2017
2	Monoclonal AntibodiesIBA 01/2018 - 01/2017
2	Tumor Necrosis Factor InhibitorsIBA 01/2017 - 01/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2021
1	Immunologic Factors (Immunomodulators)IBA 10/2021
1	C-Reactive ProteinIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	CytokinesIBA 01/2020
1	Biological ProductsIBA 01/2019
1	Alanine Transaminase (SGPT)IBA 01/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017

Therapy/Procedure

5	Therapeutics 01/2022 - 01/2016
1	Artificial Respiration (Mechanical Ventilation) 10/2021